233 related articles for article (PubMed ID: 37720231)
1. A nasal vaccine with inactivated whole-virion elicits protective mucosal immunity against SARS-CoV-2 in mice.
Tokunoh N; Tamiya S; Watanabe M; Okamoto T; Anindita J; Tanaka H; Ono C; Hirai T; Akita H; Matsuura Y; Yoshioka Y
Front Immunol; 2023; 14():1224634. PubMed ID: 37720231
[TBL] [Abstract][Full Text] [Related]
2. Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.
Hemmi T; Ainai A; Hashiguchi T; Tobiume M; Kanno T; Iwata-Yoshikawa N; Iida S; Sato Y; Miyamoto S; Ueno A; Sano K; Saito S; Shiwa-Sudo N; Nagata N; Tamura K; Suzuki R; Hasegawa H; Suzuki T
Vaccine; 2022 Sep; 40(41):5892-5903. PubMed ID: 36064667
[TBL] [Abstract][Full Text] [Related]
3. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.
Americo JL; Cotter CA; Earl PL; Liu R; Moss B
Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2202069119. PubMed ID: 35679343
[TBL] [Abstract][Full Text] [Related]
4. The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines.
Chan RWY; Liu S; Cheung JY; Tsun JGS; Chan KC; Chan KYY; Fung GPG; Li AM; Lam HS
Front Immunol; 2021; 12():744887. PubMed ID: 34712232
[TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
See RH; Zakhartchouk AN; Petric M; Lawrence DJ; Mok CPY; Hogan RJ; Rowe T; Zitzow LA; Karunakaran KP; Hitt MM; Graham FL; Prevec L; Mahony JB; Sharon C; Auperin TC; Rini JM; Tingle AJ; Scheifele DW; Skowronski DM; Patrick DM; Voss TG; Babiuk LA; Gauldie J; Roper RL; Brunham RC; Finlay BB
J Gen Virol; 2006 Mar; 87(Pt 3):641-650. PubMed ID: 16476986
[TBL] [Abstract][Full Text] [Related]
6. Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection.
Nagai M; Moriyama M; Ichinohe T
mBio; 2021 Aug; 12(4):e0159821. PubMed ID: 34399617
[TBL] [Abstract][Full Text] [Related]
7. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
Front Immunol; 2022; 13():995235. PubMed ID: 36172368
[TBL] [Abstract][Full Text] [Related]
8. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice.
Takasuka N; Fujii H; Takahashi Y; Kasai M; Morikawa S; Itamura S; Ishii K; Sakaguchi M; Ohnishi K; Ohshima M; Hashimoto S; Odagiri T; Tashiro M; Yoshikura H; Takemori T; Tsunetsugu-Yokota Y
Int Immunol; 2004 Oct; 16(10):1423-30. PubMed ID: 15314040
[TBL] [Abstract][Full Text] [Related]
9. Human immune responses elicited by an intranasal inactivated H5 influenza vaccine.
Ainai A; van Riet E; Ito R; Ikeda K; Senchi K; Suzuki T; Tamura SI; Asanuma H; Odagiri T; Tashiro M; Kurata T; Multihartina P; Setiawaty V; Pangesti KNA; Hasegawa H
Microbiol Immunol; 2020 Apr; 64(4):313-325. PubMed ID: 31957054
[TBL] [Abstract][Full Text] [Related]
10. Nasal-subcutaneous prime-boost regimen for inactivated whole-virus influenza vaccine efficiently protects mice against both upper and lower respiratory tract infections.
Shibuya M; Tamiya S; Kawai A; Yoshioka Y
Biochem Biophys Res Commun; 2021 May; 554():166-172. PubMed ID: 33798943
[TBL] [Abstract][Full Text] [Related]
11. A Single Dose of BNT162b2 Messenger RNA Vaccine Induces Airway Immunity in Severe Acute Respiratory Syndrome Coronavirus 2 Naive and Recovered Coronavirus Disease 2019 Subjects.
Martinuzzi E; Benzaquen J; Guerin O; Leroy S; Simon T; Ilie M; Hofman V; Allegra M; Tanga V; Michel E; Boutros J; Maniel C; Sicard A; Glaichenhaus N; Czerkinsky C; Blancou P; Hofman P; Marquette CH
Clin Infect Dis; 2022 Dec; 75(12):2053-2059. PubMed ID: 35579991
[TBL] [Abstract][Full Text] [Related]
12. Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice.
Lu B; Huang Y; Huang L; Li B; Zheng Z; Chen Z; Chen J; Hu Q; Wang H
Immunology; 2010 Jun; 130(2):254-61. PubMed ID: 20406307
[TBL] [Abstract][Full Text] [Related]
13. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
[TBL] [Abstract][Full Text] [Related]
14. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
[TBL] [Abstract][Full Text] [Related]
15. Differentially induced immunity in buccal and nasal mucosae after vaccination for SARS-CoV-2: Prospects for mass scale immunity-screening in large populations.
Tsamadou C; Ludwig C; Scholz J; Proffen M; Hägele J; Rode I; Körper S; Fabricius D; Jahrsdörfer B; Neuchel C; Amann E; Schrezenmeier H; Fürst D
Front Immunol; 2022; 13():999693. PubMed ID: 36466833
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 convalescence and hybrid immunity elicits mucosal immune responses.
Puhach O; Bellon M; Adea K; Bekliz M; Hosszu-Fellous K; Sattonnet P; Hulo N; Kaiser L; Eckerle I; Meyer B
EBioMedicine; 2023 Dec; 98():104893. PubMed ID: 38035462
[TBL] [Abstract][Full Text] [Related]
17. Research article antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination.
Ishizaka A; Koga M; Mizutani T; Uraki R; Yamayoshi S; Iwatsuki-Horimoto K; Yamamoto S; Imai M; Tsutsumi T; Suzuki Y; Kawaoka Y; Yotsuyanagi H
Virol J; 2023 Jul; 20(1):146. PubMed ID: 37443091
[TBL] [Abstract][Full Text] [Related]
18. An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.
Vesin B; Lopez J; Noirat A; Authié P; Fert I; Le Chevalier F; Moncoq F; Nemirov K; Blanc C; Planchais C; Mouquet H; Guinet F; Hardy D; Vives FL; Gerke C; Anna F; Bourgine M; Majlessi L; Charneau P
Mol Ther; 2022 Sep; 30(9):2984-2997. PubMed ID: 35484842
[TBL] [Abstract][Full Text] [Related]
19. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
20. Intranasal Boosting with Spike Fc-RBD of Wild-Type SARS-CoV-2 Induces Neutralizing Antibodies against Omicron Subvariants and Reduces Viral Load in the Nasal Turbinate of Mice.
Cai JP; Luo C; Wang K; Cao H; Chen LL; Zhang X; Han Y; Yin F; Zhang AJ; Chu H; Yuan S; Kok KH; To KK; Chen H; Chen Z; Jin DY; Yuen KY; Chan JF
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
